Slide background
Slide background




Safe design and operation of on site generation of oxygen 93% for medical use

ID 1668 | | Visite: 3473 | Documenti Chemicals EntiPermalink: https://www.certifico.com/id/1668

Temi: Chemicals , EIGA



Safe design and operation of on site generation of oxygen 93% for medical use

Oxygen for medicinal use is a prime requirement for all healthcare facilities for both the treatment of patients with respiratory disease and for providing additional oxygen to patients being treated within the facility.

For those hospitals and clinics, where the demand is higher, oxygen is normally distributed throughout the facility using a medical gas pipeline system.

The design requirements for the supply source used to supply medical oxygen to the pipeline system are detailed in the standard, EN ISO 7396-1 Medical gas pipeline systems; Pipeline systems for compressed medical gases and vacuum.

Two different products are included in the standard:

- Medicinal oxygen supplied from liquid oxygen vessels and/or gaseous oxygen cylinders; and
- Oxygen 93 manufactured on-site within the healthcare facility, using an oxygen concentrator unit.

Medicinal oxygen supplied either in cylinders or as a cryogenic liquid, is required to be manufactured by an approved supplier with a manufacturers licence (to demonstrate compliance with guidelines detailed in the European Commission’s Guide to Good Manufacturing Practice (GMP))

Within the European Union, the supplier of medical oxygen is required to hold a marketing authorisation in accordance with Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, detailing the clinical indications and contraindications and specific warnings for the safe use of the product.

The specification of this medical oxygen is detailed in the European Pharmacopoeia monograph for medical oxygen, which specifies a minimum purity of 99.5% oxygen.

The quality, safety and efficacy of the medical oxygen are ensured by the medical gas supplier through a quality management system under the responsibility of a qualified person.

Oxygen 93 can be manufactured on-site within the healthcare facility, under the responsibility of the healthcare facility pharmacist, using an oxygen 93 supply system and meeting the appropriate and specific quality and safety criteria for medicinal products prepared in Pharmacies (see Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme Guide PE010-4 Guideline to good practices for the preparation of medicinal products in healthcare establishment).

Oxygen 93 is not being ‘put on the market’, so it currently falls outside the regulation for the manufacture and supply of medicinal product Directive 2001/83/EC.

Oxygen 93 concentrator units are covered by the requirements for CE marking in accordance with the Medical Device Directive, (Council Directive 93/42/EEC of 14 June 1993 concerning medical devices).

The specification of the oxygen manufactured using an oxygen 93 supply system is detailed in the European Pharmacopoeia monograph for oxygen 93, which specifies the oxygen content to be between 90% and 96% and gives appropriate limits and analysis methods of other possible contaminants during the production.

As the oxygen 93 is produced by adsorbing the nitrogen from ambient air, the major contaminant in oxygen 93 is argon, which can be present up to 5%.

When the oxygen 93% monograph was introduced it was stated that the benefits of PSA oxygen (oxygen 93 per cent) are to allow production and supply of oxygen at sites where access for cylinder and liquid oxygen supply is difficult or impossible. PSA concentrators are in use in a number of fields particularly by the military (field hospitals).

The quality of the gas is very much dependent upon the performance of the equipment that produces it.

At the time of preparation of this publication, oxygen 93 is not licensed under a marketing authorisation, thus it is not evaluated by regulatory authorities and thus it cannot be considered as “equivalent medicine” for the oxygen.

EIGA 2015

Pin It


Tags: Chemicals EIGA

Articoli correlati

Ultimi archiviati Chemicals

Practical Guide on Biocidal Products Regulation
Nov 15, 2019 125

Practical Guide on Biocidal Products Regulation

Practical Guide on Biocidal Products Regulation The basic principle in the Biocidal Products Regulation ((EU) No 528/2012 (BPR)) is that a biocidal product (BP) must be authorised before it can be made available on the market or used in the European Union (EU)/ European Economic Area (EEA). This… Leggi tutto
Rettifica Decreto 9 maggio 2019 n  72
Nov 14, 2019 208

Rettifica Decreto 9 maggio 2019 n. 72

Rettifica decreto del Ministro della salute 9 maggio 2019 n. 72 Avviso di rettifica - Comunicato relativo al decreto del Ministro della salute 9 maggio 2019, n. 72 concernente il «Regolamento recante l'aggiornamento al decreto del Ministro della sanita' 21 marzo 1973, recante: "Disciplina igienica… Leggi tutto
RapportoISTISAN 1918
Nov 11, 2019 101

Metalli in prodotti cosmetici | Valutazione dei rischi per la salute

Metalli in prodotti cosmetici: procedure raccomandate per la determinazione e valutazione dei rischi per la salute ISTISAN 19/18 Il Regolamento (CE) 1223/2009 sui prodotti cosmetici contiene le disposizioni armonizzate per proteggere la salute dei consumatori (art. 3) e garantire il buon… Leggi tutto
Regolamento CE  428 2009
Nov 08, 2019 116

Regolamento (CE) N. 428/2009

Regolamento (CE) N. 428/2009 Regolamento (CE) N. 428/2009 del Consiglio del 5 maggio 2009 che istituisce un regime comunitario di controllo delle esportazioni, del trasferimento, dell’intermediazione e del transito di prodotti a duplice uso GU L 134/1 del 29.5.2009 Data di entrata in… Leggi tutto
Micotossine alimenti
Ott 30, 2019 104

Relazione controllo delle micotossine negli alimenti | anno 2018

Relazione riguardante il controllo delle micotossine negli alimenti anno 2018 A cura di Ministero della Salute Anno 2019 Il Ministero della Salute, in collaborazione con l’Istituto superiore di sanità, ha predisposto a partire dall’anno 2016 il Piano nazionale di controllo ufficiale delle… Leggi tutto

Più letti Chemicals

Regolamento  CE  852 2004
Mar 06, 2019 22088

Regolamento (CE) N. 852/2004

Regolamento (CE) N. 852/2004 Regolamento (CE) N. 852/2004 del Parlamento europeo e del Consiglio del 29 aprile 2004 sull'igiene dei prodotti alimentari GU L 139/1 del 30.4.2004 Testo consolidato 2009Modificato da: Regolamento (CE) n. 1019/2008 della Commissione del 17 ottobre 2008 (GU L 277 7… Leggi tutto
Mar 02, 2019 21088

Regolamento (CE) n. 2023/2006 (Regolamento GMP)

Regolamento (CE) n. 2023/2006 Regolamento (CE) N. 2023/2006 della Commissione del 22 dicembre 2006 sulle buone pratiche di fabbricazione dei materiali e degli oggetti destinati a venire a contatto con prodotti alimentari (Regolamento GMP - Good Manufacturing Practices) ... Il presente regolamento… Leggi tutto